No Data
Myriad Genetics Introduces Online Prenatal Genetic Testing Resource
Leerink Partners Maintains Myriad Genetics(MYGN.US) With Hold Rating, Cuts Target Price to $18
Leerink Partners Sticks to Their Hold Rating for Myriad Genetics (MYGN)
Myriad Genetics Study Shows Increased Completion Rates for Hereditary Cancer Testing Through Online Screening and Education Tools
Myriad Genetics Announces Publication Of Hereditary Cancer Risk Assessment Program Study In Obstetrics & Gynecology
Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology
905745367 OP : It will bounce back